LY393615, a novel neuronal Ca2+ and Na+ channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemia

Brain Research

Volumn 888, Issue 1, 2001, Pages 138-149

  O'Neill, Michael J ^a   Hicks, Caroline A ^a   Ward, Mark A ^a   Osborne, David J ^a   Wishart, Graham ^a   Mathews, Kusum S ^b   McLaughlin, Daniel P ^b   Stamford, Jonathan A ^b   McCarty, Deborah R ^a   Patrick, Kelly E ^a   Roman, Carlos ^a   Fleisch, Jerome H ^a   Gilmore, Jeremy ^a   Boot, John R ^a  

^a ELI LILLY AND COMPANY   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cerebral ischemia; LY393615; Neuronal calcium channel; Neuroprotection

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; LY 393615; N BUTYL [5,5 BIS (4 FLUOROPHENYL)TETRAHYDROFURAN 2 YL]METHYLAMINE; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN HYPOXIA; BRAIN ISCHEMIA; BRAIN SLICE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG PENETRATION; GERBIL; HYPOGLYCEMIA; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN ISCHEMIA; BUTYLAMINES; CALCIUM CHANNEL BLOCKERS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FURANS; GERBILLINAE; HIPPOCAMPUS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; NEUROPROTECTIVE AGENTS; PURKINJE CELLS; RATS; RATS, WISTAR; SODIUM CHANNEL BLOCKERS;

EID: 0035808594     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)03043-2     Document Type: Article

References (55)

1. Drugs acting on calcium channels: Potential treatment for ischemic stroke
2. P/Q-type Ca2+ channel blocker ω-conotoxin IVA protects against brain injury after focal ischemia in rats
3. Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia
4. SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and mice
5. 2+ channels and in gerbil global cerebral ischaemia
6. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model
7. 2+ antagonist is neuroprotective in two models of cerebral ischaemia
8. LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global cerebral ischaemia
9. 2+-channel blocker prevents CA1 injury 24 h following severe forebrain ischemia and reduces infarction following focal ischemia
10. Excitotoxic cell death
11. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil
12. The pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia
13. Effect of ischemia on in vivo release of striatal dopamine, glutamate and gamma-aminobutyric acid studied by intracerebral microdialysis
14. 2+ channels controlling presynaptic release of glutamate
15. Failure of levemopamil to improve histological outcome following tempory occlusion of the middle cerebral artery in cats
16. Evaluation of glycine site antagonists of the NMDA receptor in global cerebral ischaemia
17. Neuronal apoptosis: Current understanding of molecular mechanisms and potential role in ischemic brain injury
18. (S)-Emopamil protects against global brain injury in rats
19. Exploration of P-type Ca2+ channels as drug targets for the treatment of epilepsy or ischemic stroke
20. Stereoselective effects of 2,3-benzodiazepines in vivo: Electrophysiology and neuroprotection studies
21. Semiquantitative assessment of ischaemic damage in brain slices by Tetrazolium Red
22. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man
23. Postischemic (S)-emopamil therapy ameliorates focal ischemic brain injury in rats
24. 2 antagonist, markedly reduces infarct size following middle cerebral artery occlusion in the rat
25. Caspases: Killer proteases
26. + channel inhibitors in vitro and in global cerebral ischaemia in vivo
27. Neuroprotective effects of the antioxidant LY231617 and NO synthase inhibitors in global cerebral ischaemia
28. Decahydroisoquinolines: Novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia
29. LY377770, a novel iGlu5 kainate antagonist with neuroprotective properties in global and focal cerebral ischaemia
30. SNX-111, a novel presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits
31. Selective N-type calcium channel antagonist omega conotoxin MVIIA is neuroprotective against hypoxia neurodegeneration in organotypic hippocampal-slice cultures
32. Neuronal protective effects of calcium channel antagonists in cerebral ischaemia
33. Endothelin-1 induced middle cerebral artery occlusion: Pathological consequences and neuroprotective effects of MK-801
34. Perivascular microapplication of endothelin-1: A new model of focal cerebral ischaemia in the rat
35. 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline: A neuro-protectant for cerebral ischemia
36. The neuroprotective effect of NNC 09-0026, a new calcium channel blocker in global ischemia
37. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia
38. Pathophysiology and treatment of focal cerebral ischemia, Part I: Pathophysiology
39. Pathophysiology and treatment of focal cerebral ischemia, Part II: Mechanisms and drug treatment
40. Identification of calcium channels involved in neuronal injury in rat hippocampal slices subjected to oxygen and glucose deprivation
41. Postischemic treatment with the omega-conopeptide SNX-111 protects the rat brain against ischemic damage
42. A selective N-type calcium channel antagonist reduces extracellular glutamate release and infarct volume in focal cerebral ischemia
43. Electrophysiological characterization of NCC1048, a novel calcium channel blocker
44. Real time measurement of dopamine release in an in vitro model of neostriatal ischaemia
45. Involvement of N- and P/Q but not L- of T-type voltage-gated calcium channels in ischaemia-induced striatal dopamine release in vitro
46. Reflections on calcium channel diversity, 1988-1994
47. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia
48. Synthesis and biological activity of the neuronal calcium blocker 2-amino-1-(2,5-dimethoxyphenyl)-5-trifluoromethyl benzimidazole (NS-649)
49. Caspases and caspase inhibitors
50. Agonists and antagonists for excitatory amino acid receptors
51. The effects of SB 206284A, a novel neuronal calcium channel antagonist, in models of cerebral ischemia
52. Time-course and treatment response with SNX-11, an N-type channel blocker, in a rodent model of focal cerebral ischema using diffusion-weighted MRI
53. Reversible middle cerebral artery occlusion without craniectomy in rats
54. The omega-conopeptide SNX-111, an N-type calcium-channel blocker, dramatically ameliorates brain damage due to transient focal ischemia